Trial Information
A Non-interventional Study of Avastin in Combination With Paclitaxel for First Line Treatment in HER2 Negative Metastatic Breast Cancer
Inclusion Criteria:
- Adult patients, >/= 18 years of age
- Locally recurrent or metastatic breast cancer
- No prior treatment for metastatic or locally recurrent disease
- Eastern Cooperative Oncology Group (ECOG) performance status 0-2
Exclusion Criteria:
- History or clinical evidence of brain metastases
- Pregnancy
- Uncontrolled hypertension ( systolic > 150 mmHg and/or diastolic > 100 mmHg) or
clinically significant (i.e. active) cardiovascular disease
- Major surgical procedure or significant traumatic injury within 28 days prior to
enrolment
Type of Study:
Observational
Study Design:
Observational Model: Cohort, Time Perspective: Prospective
Outcome Measure:
Progression-free survival
Outcome Time Frame:
approximately 2.5 years
Safety Issue:
No
Principal Investigator
Clinical Trials
Investigator Role:
Study Director
Investigator Affiliation:
Hoffmann-La Roche
Authority:
Croatia: Ministry of Health
Study ID:
ML25312
NCT ID:
NCT01661153
Start Date:
March 2011
Completion Date:
October 2013
Related Keywords:
- Breast Cancer
- Breast Neoplasms